A phase II basket study of necitumumab for EGFR amplification positive m etastatic solid tumor : WJOG15021M
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
Interventions: Necitumumab 800 mg, IV over 60 minutes, given o n days 1 and 8, repeated every 3 weeks Primary outcome(s): Objective response rate: ORR Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose
创建时间：
2022-11-15
